Alice M. Turner

List of Publications by Year
in descending order

178 papers	4,436 citations	109264 35 h-index	123376 61 g-index
249 all docs	249 docs citations	249 times ranked	5726 citing authors

#	Article	IF	Citations
1	Relationship of Sputum Color to Nature and Outpatient Management of Acute Exacerbations of COPD. Chest, 2000, 117, 1638-1645.	0.4	462
2	Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax, 2015, 70, 617-624.	2.7	258
3	European Respiratory Society statement: diagnosis and treatment of pulmonary disease in Î±₁-antitrypsin deficiency. European Respiratory Journal, 2017, 50, 1700610.	3.1	244
4	Availability of 25-Hydroxyvitamin D3 to APCs Controls the Balance between Regulatory and Inflammatory T Cell Responses. Journal of Immunology, 2012, 189, 5155-5164.	0.4	172
5	The vitamin D axis in the lung: a key role for vitamin D-binding protein. Thorax, 2010, 65, 456-462.	2.7	166
6	Metalloproteinases in idiopathic pulmonary fibrosis. European Respiratory Journal, 2011, 38, 1461-1467.	3.1	130
7	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respiratory Medicine,the, 2015, 3, 443-450.	5.2	125
8	Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax, 2011, 66, 205-210.	2.7	97
9	Rate of progression of lung function impairment in Â1-antitrypsin deficiency. European Respiratory Journal, 2009, 33, 1338-1344.	3.1	86
10	Î±-1-Antitrypsin deficiency: clinical variability, assessment, and treatment. Trends in Molecular Medicine, 2014, 20, 105-115.	3.5	76
11	The role of the endothelium in asthma and chronic obstructive pulmonary disease (COPD). Respiratory Research, 2017, 18, 20.	1.4	76
12	Alpha One Antitrypsin Deficiency: From Gene to Treatment. Respiration, 2007, 74, 481-492.	1.2	74
13	Tuberculosis Incidence Correlates with Sunshine: An Ecological 28-Year Time Series Study. PLoS ONE, 2013, 8, e57752.	1.1	74
14	ANCA-associated vasculitis is linked to carriage of the Z allele of Î±₁ antitrypsin and its polymers. Annals of the Rheumatic Diseases, 2011, 70, 1851-1856.	0.5	69
15	The genetics of chronic obstructive pulmonary disease. Respiratory Research, 2006, 7, 130.	1.4	68
16	Systematic review: the natural history of alphaâ€1 antitrypsin deficiency, and associated liver disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 877-885.	1.9	67
17	PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPD. Thorax, 2015, 70, 939-945.	2.7	64
18	Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review. International Journal of COPD, 2017, Volume 12, 1295-1308.	0.9	64

#	Article	IF	Citations
19	Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis. Health Technology Assessment, 2015, 19, 1-516.	1.3	64
20	Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trial. Lancet Respiratory Medicine,the, 2016, 4, 720-730.	5.2	63
21	The Early Mobility Bundle: a simple enhancement of therapy which may reduce incidence of hospital-acquired pneumonia and length of hospital stay. Journal of Hospital Infection, 2014, 88, 34-39.	1.4	62
22	Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. European Respiratory Journal, 2021, 58, 2004240.	3.1	58
23	Hepatic-targeted RNA interference provides robust and persistent knockdown of alpha-1 antitrypsin levels in ZZ patients. Journal of Hepatology, 2018, 69, 378-384.	1.8	56
24	Self-management of health care behaviors for COPD: a systematic review and meta-analysis. International Journal of COPD, 2016, 11, 305.	0.9	53
25	A simple algorithm for the identification of clinical COPD phenotypes. European Respiratory Journal, 2017, 50, 1701034.	3.1	53
26	Smoke exposure as a determinant of autoantibody titre in Â1-antitrypsin deficiency and COPD. European Respiratory Journal, 2011, 37, 32-38.	3.1	52
27	Sex differences between women and men with COPD: A new analysis of the 3CIA study. Respiratory Medicine, 2020, 171, 106105.	1.3	50
28	Tumor Necrosis Factorâ€“Î± rs361525 Polymorphism Is Associated with Increased Local Production and Downstream Inflammation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 192-199.	2.5	48
29	Vitamin D Deficiency and Acute Lung Injury. Inflammation and Allergy: Drug Targets, 2013, 12, 253-261.	1.8	43
30	Pharmacotherapies for COPD. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2013, 7, CCRPM.S7211.	0.5	40
31	The association between asthma and obstructive sleep apnea (OSA): A systematic review. Journal of Asthma, 2019, 56, 118-129.	0.9	40
32	Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?. International Journal of COPD, 2016, Volume 11, 1745-1756.	0.9	39
33	CT densitometry in emphysema: a systematic review of its clinical utility. International Journal of COPD, 2018, Volume 13, 547-563.	0.9	39
34	Interventions for the management and prevention of sarcopenia in the critically ill: A systematic review. Journal of Critical Care, 2019, 50, 287-295.	1.0	39
35	Variability of sputum inflammatory mediators in COPD and Î±₁-antitrypsin deficiency. European Respiratory Journal, 2012, 40, 561-569.	3.1	38
36	Lung density associates with survival in alpha 1 antitrypsin deficient patients. Respiratory Medicine, 2016, 112, 81-87.	1.3	36

#	Article	IF	Citations
37	Diagnosis and management of Î±1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Research, 2019, 5, 00171-2018.	1.1	36
38	Outdoor air pollution is associated with rapid decline of lung function in Â-1-antitrypsin deficiency. Occupational and Environmental Medicine, 2010, 67, 556-561.	1.3	35
39	Clinically relevant subgroups in COPD and asthma. European Respiratory Review, 2015, 24, 283-298.	3.0	35
40	The effect of domiciliary noninvasive ventilation on clinical outcomes in stable and recently hospitalized patients with COPD: a systematic review and meta-analysis. International Journal of COPD, 2016, Volume 11, 2269-2286.	0.9	32
41	The European Alpha-1 Research Collaboration (EARCO): a new ERS Clinical Research Collaboration to promote research in alpha-1 antitrypsin deficiency. European Respiratory Journal, 2019, 53, 1900138.	3.1	32
42	Does Continuous Positive Airway Pressure (CPAP) treatment of obstructive sleep apnoea (OSA) improve asthma-related clinical outcomes in patients with co-existing conditions?- A systematic review. Respiratory Medicine, 2018, 143, 18-30.	1.3	30
43	A care-bundles approach to improving standard of care in AECOPD admissions: results of a national project: TableÂ1. Thorax, 2015, 70, 992-994.	2.7	29
44	Phenotypic Differences in Alpha 1 Antitrypsin-Deficient Sibling Pairs May Relate to Genetic Variation. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 353-359.	0.7	28
45	Circulating DBP level and prognosis in operated lung cancer: an exploration of pathophysiology. European Respiratory Journal, 2013, 41, 410-416.	3.1	28
46	Supported self-management for patients with COPD who have recently been discharged from hospital: a systematic review and meta-analysis. International Journal of COPD, 2015, 10, 853.	0.9	28
47	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. Gut, 2022, 71, 415-423.	6.1	28
48	The role of iron in pulmonary pathology. Multidisciplinary Respiratory Medicine, 2015, 10, 34.	0.6	26
49	Identification of novel vascular targets in lung cancer. British Journal of Cancer, 2015, 112, 485-494.	2.9	25
50	British Thoracic Society community-acquired pneumonia care bundle: results of a national implementation project: TableÂ1. Thorax, 2016, 71, 288-290.	2.7	23
51	Utility of respiratory wardâ€based <scp>NIV</scp> in acidotic hypercapnic respiratory failure. Respirology, 2014, 19, 1241-1247.	1.3	22
52	Model-based evaluation of the long-term cost-effectiveness of systematic case-finding for COPD in primary care. Thorax, 2019, 74, 730-739.	2.7	22
53	Evaluation of oxygen prescription in relation to hospital admission rate in patients with chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 2014, 14, 127.	0.8	21
54	Cohort Profile: The Birmingham Chronic Obstructive Pulmonary Disease (COPD) Cohort Study. International Journal of Epidemiology, 2017, 46, dyv350.	0.9	21

#	Article	IF	Citations
55	Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. BMC Medicine, 2018, 16, 33.	2.3	21
56	The cost-effectiveness of domiciliary non-invasive ventilation in patients with end-stage chronic obstructive pulmonary disease: a systematic review and economic evaluation. Health Technology Assessment, 2015, 19, 1-246.	1.3	21
57	Outdoor air pollution is associated with disease severity in Â1-antitrypsin deficiency. European Respiratory Journal, 2009, 34, 346-353.	3.1	20
58	Ventilatory responses to muscle metaboreflex activation in chronic obstructive pulmonary disease. Journal of Physiology, 2016, 594, 6025-6035.	1.3	20
59	Protocol for the EARCO Registry: a pan-European observational study in patients with Î±₁-antitrypsin deficiency. ERJ Open Research, 2020, 6, 00181-2019.	1.1	20
60	Spirometric and Gas Transfer Discordance in Î±1-Antitrypsin Deficiency. Chest, 2014, 145, 1316-1324.	0.4	18
61	Visualization and quantitation of GLUT4 translocation in human skeletal muscle following glucose ingestion and exercise. Physiological Reports, 2015, 3, e12375.	0.7	18
62	Adapting to domiciliary non-invasive ventilation in chronic obstructive pulmonary disease: A qualitative interview study. Palliative Medicine, 2015, 29, 268-277.	1.3	18
63	Predicting Postoperative Lung Function Following Lung Cancer Resection: A Systematic Review and Meta-analysis. EClinicalMedicine, 2019, 15, 7-13.	3.2	18
64	Cardiovascular disease in chronic obstructive pulmonary disease: a narrative review. Thorax, 2022, 77, 939-945.	2.7	18
65	Experimental and investigational drugs for the treatment of alpha-1 antitrypsin deficiency. Expert Opinion on Investigational Drugs, 2019, 28, 891-902.	1.9	17
66	Global Initiative for Chronic Obstructive Lung Disease 2011 Symptom/Risk Assessment in Î± 1 -Antitrypsin Deficiency. Chest, 2013, 144, 1152-1162.	0.4	16
67	TargetCOPD: a pragmatic randomised controlled trial of targeted case finding for COPD versusroutine practice in primary care: protocol. BMC Pulmonary Medicine, 2014, 14, 157.	0.8	16
68	IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer. European Respiratory Journal, 2017, 49, 1600711.	3.1	16
69	Can process mining automatically describe care pathways of patients with long-term conditions in UK primary care? A study protocol. BMJ Open, 2018, 8, e019947.	0.8	14
70	Small Airways Disease, Biomarkers and COPD: Where are We?. International Journal of COPD, 2021, Volume 16, 351-365.	0.9	14
71	What Do Alpha-1 Antitrypsin Levels Tell Us About Chronic Inflammation in COPD?. Archivos De Bronconeumologia, 2020, 56, 72-73.	0.4	14
72	Pulmonary function test and computed tomography features during follow-up after SARS, MERS and COVID-19: a systematic review and meta-analysis. ERJ Open Research, 2022, 8, 00056-2022.	1.1	14

#	Article	IF	Citations
73	Alpha-1 Antitrypsin Deficiency: New Developments in Augmentation and Other Therapies. BioDrugs, 2013, 27, 547-558.	2.2	13
74	Health status decline in Î±-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies?. Respiratory Research, 2018, 19, 137.	1.4	12
75	A novel model and molecular therapy for Z alpha-1 antitrypsin deficiency. Mammalian Genome, 2012, 23, 241-249.	1.0	11
76	Free light chains: potential biomarker and predictor of mortality in alpha-1-antitrypsin deficiency and usual COPD. Respiratory Research, 2016, 17, 34.	1.4	11
77	ICS Use May Modify FEV₁ Decline in Î±₁-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils. Respiration, 2018, 95, 114-121.	1.2	11
78	Development and Relevance of Hypercapnia in COPD. Canadian Respiratory Journal, 2021, 2021, 1-8.	0.8	11
79	Relationship of the 2011 Global Initiative for Chronic Obstructive Lung Disease Strategy to Clinically Relevant Outcomes in Individuals with Î±1-Antitrypsin Deficiency. Annals of the American Thoracic Society, 2014, 11, 859-864.	1.5	10
80	Protocol for a systematic review and economic evaluation of the clinical and cost-effectiveness of non-hospital-based non-invasive ventilation (NIV) in patients with stable end-stage COPD with hypercapnic respiratory failure. Systematic Reviews, 2014, 3, 32.	2.5	10
81	Ward-Based Non-Invasive Ventilation in Acute Exacerbations of COPD: A Narrative Review of Current Practice and Outcomes in the UK. Healthcare (Switzerland), 2018, 6, 145.	1.0	10
82	Presentation and prognosis of liver disease in alpha-1 antitrypsin deficiency. Expert Review of Gastroenterology and Hepatology, 2018, 12, 745-747.	1.4	10
83	Memory, attention and fluency deficits in COPD may be a specific form of cognitive impairment. ERJ Open Research, 2019, 5, 00229-2018.	1.1	10
84	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. ERJ Open Research, 2020, 6, 00253-2020.	1.1	10
85	Obstacles to Early Diagnosis and Treatment of Alpha-1 Antitrypsin Deficiency: Current Perspectives . Therapeutics and Clinical Risk Management, 2020, Volume 16, 1243-1255.	0.9	10
86	A Systematic Review of Nudge Interventions to Optimize Medication Prescribing. Frontiers in Pharmacology, 2022, 13, 798916.	1.6	10
87	Early ward-based acute noninvasive ventilation: a paper that changed practice. Breathe, 2018, 14, 153-155.	0.6	9
88	Pulmonary MicroRNA Changes Alter Angiogenesis in Chronic Obstructive Pulmonary Disease and Lung Cancer. Biomedicines, 2021, 9, 830.	1.4	9
89	Accuracy and cost-effectiveness of different screening strategies for identifying undiagnosed COPD among primary care patients (â‰¥40 years) in China: a cross-sectional screening test accuracy study: findings from the Breathe Well group. BMJ Open, 2021, 11, e051811.	0.8	9
90	Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise. Npj Primary Care Respiratory Medicine, 2022, 32, 6.	1.1	9

#	Article	IF	Citations
91	Temporal trends in survival following wardâ€based NIV for acute hypercapnic respiratory failure in patients with COPD. Clinical Respiratory Journal, 2019, 13, 184-188.	0.6	8
92	Pneumonia in exacerbations of COPD: what is the clinical significance?. ERJ Open Research, 2020, 6, 00282-2019.	1.1	8
93	Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic. International Journal of COPD, 2021, Volume 16, 2983-2996.	0.9	8
94	Cost-effectiveness of domiciliary non-invasive ventilation in patients with chronic obstructive pulmonary disease. Thorax, 2022, 77, 976-986.	2.7	8
95	Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Faculty Reviews, 2020, 9, 1.	1.7	8
96	Late presentation of acute hypercapnic respiratory failure carries a high mortality risk in COPD patients treated with ward-based NIV. Respiratory Medicine, 2019, 151, 128-132.	1.3	7
97	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 8-17.	0.7	7
98	Safety and efficacy of P2X3 antagonist BAY 1902607 in refractory chronic cough. , 2020, , .		7
99	Managing panniculitis in alpha-1 antitrypsin deficiency: Systematic review of evidence behind treatment. World Journal of Dermatology, 2018, 7, 1-8.	0.5	7
100	External Validation Of The Updated ADO Score In COPD Patients From The Birmingham COPD Cohort . International Journal of COPD, 2019, Volume 14, 2395-2407.	0.9	6
101	Experience-based co-design to improve a pulmonary rehabilitation programme. International Journal of Health Care Quality Assurance, 2019, 32, 778-787.	0.2	6
102	Chronic Obstructive Pulmonary Disease: The Present and Future. Biomedicines, 2022, 10, 499.	1.4	6
103	Effects of short-term graded dietary carbohydrate intake on intramuscular and whole body metabolism during moderate-intensity exercise. Journal of Applied Physiology, 2021, 131, 376-387.	1.2	5
104	The impact of <scp>COVID</scp>â€19 on acute nonâ€invasive ventilation services: A case for change. Respirology, 2021, 26, 1106-1109.	1.3	5
105	Prevalence, Pattern, Risks Factors and Consequences of Antibiotic Resistance in COPD: A Systematic Review. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 672-682.	0.7	5
106	A Systematic Review and Meta-Analysis of the Prevalence and Impact of Pulmonary Bacterial Colonisation in Stable State Chronic Obstructive Pulmonary Disease (COPD). Biomedicines, 2022, 10, 81.	1.4	5
107	CTLA4 polymorphisms and COPD. European Respiratory Journal, 2010, 35, 457-458.	3.1	4
108	Auto-Antibodies and Inflammation. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 959-960.	2.5	4

#	Article	IF	Citations
109	Reforming respiratory outpatient services: a before-and-after observational study assessing the impact of a quality improvement project applying British Thoracic Society criteria to the discharge of patients to primary care. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2013, 22, 72-78.	2.5	4
110	Assessing the extent of drug interactions among patients with multimorbidity in primary and secondary care in the West Midlands (UK): a study protocol for the Mixed Methods Multimorbidity Study (MiMMS). BMJ Open, 2017, 7, e016713.	0.8	4
111	Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2021, 8, 162-176.	0.5	4
112	Long-term effect of Î±1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database. ERJ Open Research, 2021, 7, 00194-2021.	1.1	4
113	Ambulatory Oxygen for Exercise-Induced Desaturation and Dyspnea in Chronic Obstructive Pulmonary Disease (COPD): Systematic Review and Meta-Analysis. Chronic Obstructive Pulmonary Diseases (Miami,) Tj ETQq1 1 0.784314 rgBT /O	1.5	4
114	Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group. International Journal of COPD, 2022, Volume 17, 53-64.	0.9	4
115	A human factors approach to quality improvement in oxygen prescribing. Clinical Medicine, 2022, 22, 153-159.	0.8	4
116	Ward-Based Noninvasive Ventilation for Acute Hypercapnic Respiratory Failure Unrelated to Chronic Obstructive Pulmonary Disease. Canadian Respiratory Journal, 2021, 2021, 1-7.	0.8	4
117	Impact of COVID-19 in Patients With Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration. Archivos De Bronconeumologia, 2022, 58, 840-842.	0.4	4
118	MUC5B: a good target for future therapy in pulmonary fibrosis?. Thorax, 2013, 68, 401-401.	2.7	3
119	Fifty Years On: GWAS Confirms the Role of a Rare Variant in Lung Disease. PLoS Genetics, 2013, 9, e1003768.	1.5	3
120	Alpha-1 Antitrypsin Deficiency: A Predisposing Factor for the Development of Pulmonary Langerhans Cell Histiocytosis. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 206-209.	0.5	3
121	Bilevel positive airway pressure ventilation for non-COPD acute hypercapnic respiratory failure patients: A systematic review and meta-analysis. Annals of Thoracic Medicine, 2021, 16, 306.	0.7	3
122	Why is Disease Penetration so Variable in Alpha-1 Antitrypsin Deficiency? The Contribution of Environmental Factors. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2020, 7, 280-289.	0.5	3
123	Molecular Determinants of Acute Muscle Wasting in the ICU. Critical Care Medicine, 2013, 41, 1141-1142.	0.4	2
124	FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD. BMJ Open, 2021, 11, e042526.	0.8	2
125	Relationship between Depression and Anxiety, Health Status and Lung Function in Patients with Alpha-1 Antitrypsin Deficiency. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 621-629.	0.7	2
126	Using a rapid prioritisation process to identify health research priorities in LMICs. , 2018, , .		2

#	Article	IF	Citations
127	Re-evaluating COPD Risk. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 837-838.	2.5	1
128	Serum free light chains and the adaptive immune response in usual and alpha-1-antitrypsin deficiency-related chronic obstructive pulmonary disease. Lancet, The, 2014, 383, S28.	6.3	1
129	Automated conflict resolution between multiple clinical pathways: a technology report. BMJ Health and Care Informatics, 2018, 25, 142-148.	1.4	1
130	Identifying the at risk smokers: who goes on to get COPD?. European Respiratory Journal, 2019, 54, 1901613.	3.1	1
131	Interventions to Increase the Rate of Influenza and Pneumococcal Vaccination in Patients with Chronic Obstructive Pulmonary Disease: A Scoping Review. Medicina (Lithuania), 2019, 55, 277.	0.8	1
132	Evolving indications and demographics for domiciliary Non-Invasive Ventilation (NIV) at an acute hospital based NIV service. , 2018, , .		1
133	Development of the Birmingham Lung Improvement Studies (BLISS) prognostic score for COPD patients in primary care: data from the Birmingham COPD cohort. , 2019, , .		1
134	Treatment of lung disease in patients with AATD. , 2019, , 78-92.		1
135	Alpha-1 antitrypsin (A1-PI) treatment slows emphysema progression independent of baseline FEV1. , 2017, , .		1
136	Comparison of outcomes in augmentation naÃ¨ve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. , 2019, , .		1
137	External validation of the updated ADO score to predict mortality in COPD patients from the Birmingham COPD cohort. , 2019, , .		1
138	Personalising exacerbation prediction strategies in chronic obstructive pulmonary disease. World Journal of Respirology, 2020, 10, 11-16.	0.5	1
139	Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. Faculty Reviews, 2020, 9, 1.	1.7	1
140	Case-finding and improving patient outcomes for chronic obstructive pulmonary disease in primary care: the BLISS research programme including cluster RCT. Programme Grants for Applied Research, 2021, 9, 1-148.	0.4	1
141	ISQUA18-2485A Patient-Centred Approach to Redesigning Information Sources and Flows of a Pulmonary Rehabilitation Services. International Journal for Quality in Health Care, 2018, 30, 40-41.	0.9	0
142	P2.06-28 Assessment of Chest Wall Motion Using Structured Light Plethysmography (SLP) in Mesothelioma and Benign Pleural Disease. Journal of Thoracic Oncology, 2018, 13, S753.	0.5	0
143	Letter: unlikely liver bedfellowsâ€"alphaâ€1 antitrypsin deficiency and granulomatosis with polyangiitis. Author's reply. Alimentary Pharmacology and Therapeutics, 2018, 48, 233-233.	1.9	0
144	Alpha 1 antitrypsin deficiency: a rare multisystem disease, predominantly affecting the lung. Expert Opinion on Orphan Drugs, 2019, 7, 315-326.	0.5	0

#	Article	IF	Citations
145	Modernising case finding for Î±₁-antitrypsin deficiency by DNA sequencing of COPD patients. European Respiratory Journal, 2020, 56, 2002628.	3.1	0
146	What Do Alpha-1 Antitrypsin Levels Tell Us About Chronic Inflammation in COPD?. Archivos De Bronconeumologia, 2020, 56, 72-73.	0.4	0
147	Respiratory Sequelae Following SARS, MERS, and COVID-19: A Systematic Review and Meta-Analysis of Pulmonary Function Tests and CT Features. SSRN Electronic Journal, 0, , .	0.4	0
148	Colour vision deficiency and sputum colour charts in COPD patients: an exploratory mixed-method study. Npj Primary Care Respiratory Medicine, 2021, 31, 13.	1.1	0
149	Nephrotic syndrome secondary to alpha-1 antitrypsin deficiency. BMJ Case Reports, 2021, 14, e240288.	0.2	0
150	The ventilatory response to muscle metaboreflex stimulation in patients with COPD. FASEB Journal, 2013, 27, 712.3.	0.2	0
151	Genetic influences on lung function decline in AATD. , 2015, , .		0
152	TargetCOPD: A pragmatic randomised controlled trial of targeted case finding for COPDversusroutine practice in primary care. , 2015, , .		0
153	Blood eosinophils as a biomarker in alpha 1 anti trypsin deficiency. , 2015, , .		0
154	Vitamin D supplementation in health and latent tuberculosis promotes regulatory T cell expression. , 2016, , .		0
155	Vitamin D binding protein (DBP) levels during tuberculosis treatment are affected by DBP genotype / haplotype but not by total vitamin D levels. , 2016, , .		0
156	Vitamin D supplementation in health and latent tuberculosis significantly influences T lymphocyte cytokine response. , 2016, , .		0
157	Systematic review of the relevance of CT densitometry in patients with COPD and AATD. , 2016, , .		0
158	Physician perspectives: barriers to diagnosing and treating severe AATD. , 2017, , .		0
159	Decline in health status in alpha1 antitrypsin deficiency. , 2017, , .		0
160	The impact of late presentation of acidotic hypercapnic respiratory failure in hospitalised COPD patients on outcome following non-invasive ventilation.. , 2018, , .		0
161	Effect of screening for undiagnosed COPD on respiratory hospitalisation and mortality; 4 year follow up of the TargetCOPD trial. , 2019, , .		0
162	Risk charts of five-year mortality in COPD patients. , 2019, , .		0

#	Article	IF	Citations
163	Determinants of arterial stiffness in Alpha-1 Antitrypsin Deficiency. , 2020, , .		0
164	Personalizing liver targeted treatments and transplantation for patients with alpha-1 antitrypsin deficiency. Expert Review of Precision Medicine and Drug Development, 2021, 6, 65-78.	0.4	0
165	Unravelling the risk of (intermediate) antitrypsin deficiency. Thorax, 2021, 76, 214-215.	2.7	0
166	Liver Disease in Alpha-1-Antitrypsin Deficiency. , 2020, , 377-389.		0
167	Respiratory Physiological Sequelae following Coronavirus Infection: A Systematic Review. , 2021, , .		0
168	Thoracic Radiological SequelaeÂafter Coronavirus Infection: A Systematic Review. , 2021, , .		0
169	Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients. , 2021, , .		0
170	Late Breaking Abstract - COVID-19 Infodemic and Health-Related Quality of Life (HRQoL) in Patients with Chronic Respiratory Diseases (CRDs). , 2021, , .		0
171	Baseline characteristics of patients enrolled in the EARCO prospective registry of alpha-1 antitrypsin deficiency: preliminary results. , 2021, , .		0
172	A multicentre observational study of the prevalence, management and outcomes of subsegmental pulmonary embolism. , 2020, , .		0
173	Identification of important respiratory research themes relevant to primary care: qualitative analysis of round 1 of the 2020 International Primary Care Respiratory Group (IPCRG) Research Prioritisation Exercise. , 2020, , .		0
174	Tackling COPD misdiagnosis in primary care through integrated care. , 2020, , .		0
175	Research priorities in alpha-1 antitrypsin deficiency (AATD) for healthcare professionals. , 2020, , .		0
176	Sex differences in COPD outcome in 5,355 women with COPD: A new analysis of the 3CIA study. , 2020, , .		0
177	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging systems: a pooled analysis of individual patient data. , 2020, , .		0
178	Automated conflict resolution for patients with multiple morbidity being treated using more than one set of single condition clinical guidance: A case study. Computers in Biology and Medicine, 2022, 144, 105381.	3.9	0